Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date. TAGline - Volume 8 Issue 7 - September 2001
| Development Terminated | ||
| drug | pharmaceutical | comment |
| GW420867X/HBY1293 | GlaxoSmithKline | JAIDS 2000; also summer IAS meeting |
| ALX40-4C | Allelix Pharmaceuticals | Formulation difficulties, lack of efficacy |
| AMD3100 | AnorMed Inc. | Cardiac arrhythmias at high doses, lack of efficacy at low |
| PD-178390 | Parke-Davis | Casualty of Pfizer merger |
| CI-1012 | Parke-Davis | Casualty of Pfizer merger |
| PNU-142721 | Pharmacia & Upjohn | Casualty of P&U’s decision to leave HIV field |
| NSC 651016 | Pharmacia & Upjohn | Casualty of P&U’s decision to leave HIV field |
| UC781 | Biosyn Inc. | Being developed as topical microbicide |
| zintevir/AR-177 | Antigenics (formerly Aronex) | Terminated subsequent to takeover and poor results |
| Clinical Hold | ||
| drug | pharmaceutical | comment |
| emtricitabine/FTC/Coviracil | Triangle/Abbott | Submission of NDA to be significantly delayed |
| (-)dOTC/BCH-10618/SPD754 | Shire Pharmaceuticals PLC | Deaths in monkeys |
| capravirine/S-1153/AG-1549 | Agouron (Pfizer) | Vasculitis in dogs may mean curtains for cap. |
| mozenavir/DMP-450 | DuPont (now BMS) | Electro-cardiographic abnormalities in animals |
| Glacial Development | ||
| drug | pharmaceutical | comment |
| Pentafuside/T-20 | Trimeris/Roche | Phase III; awaiting construction of peptide plant |
| T-1249 | Trimeris/Roche | Phase I; longer half-life may allow QD dosing |
| Late Pipeline | ||
| drug | pharmaceutical | comment |
| tenofovir/Viread | Gilead | FDA hearing set for October 3; Expanded Access info |
| emivirine/MKC-442/Coactinon | Triangle/Abbott | Triangle hopes to file NDA by year end; ICAAC |
| Middle Pipeline | ||
| drug | pharmaceutical | comment |
| atazanavir/BMS-232632 | Bristol-Myers Squibb | Moving slowly but deliberately through phase II |
| tipranavir | Boehringer-Ingelheim | "Trinity of major obstacles," paper at summer IAS |
| VX-175/GW433908 | Vertex/GlaxoSmithKline | Amprenavir prodrug, PK dose-ranging at 8CROI |
| SCH-C | Schering/Praecis | Recently released from clinical hold, but future dim; IAS paper |
| PRO 542 | Progenics Pharmaceuticals | Phase II, being studied in combination with T-20 |
| DPC-083 | DuPont (now BMS) | Eyed to hit market in 2003; paper at 7CROI |
| Deep Pipeline | ||
| drug | pharmaceutical | comment |
| dADP/amdoxovir | Triangle Pharmaceuticals | Phase I/II dose ranging study presented at 8CROI |
| TMC-120, 125 | Tibotec/Virco | "Resistant repellent"; Russian-Polish study at 8CROI |
| TMC-126 | Tibotec/Virco | Paper at 8CROI |
| DPC-961, DPC-963 | DuPont (BMS) | Atazanavir may take priority over these |
| Calanolide-A | SarawakMed | Paper on this at 7CROI |
| GPG-NH2 | Tripep AB/Karolinska Institute | Early activity in humans not too impressive |
| SCH-D | Schering/Praecis | Follow-up compound to SCH-C |
| UK-427,857 | Pfizer | Said to be moving into Phase I "soon" |
| DPC-681, DPC-684 | DuPont (BMS) | Phase I studies on-going; paper at 8CROI |
| AMD-3465, 8445, 8664 | AnorMed | AMD8664 is orally available analogue of AMD3100 |
| TAK-779 | Takeda Pharmaceuticals | Being studied in combination with T-20 |
| HE2000 | Hollis-Eden Pharmaceuticals | Phase I/II enrolling in U.S.; info from company, other |
| PRO 140 | Progenics Pharmaceuticals | Moving into Phase I/II; press release |
| PRO 367 | Progenics Pharmaceuticals | Phase I recently completed |
| /Hu5A8 | Tanox Biosystems, Inc. | Phase I clinical study began 8/1/01 |
| PEHRG214 | Virionyx | Phase I at Boston Deaconess Hospital, 3/01 |
| HIV NCp7 | Achillion Pharmaceuticals | Pre-clinical; also in Phase I for HBV; see CRADA announcement |
| SPD-756 | Shire Pharmaceuticals PLC | Formerly BCH-13520; company press release |
| Fd4C/ACH-126,443 | Achillion Pharmaceuticals | L. Dunkle on this, but will it go the way of other ‘F’ drugs? |
| 5-helix | Howard Hughes Medical Inst. | Science 2001, 291: 884-888 |
| ADA (azidocarbonamide) | Hubriphar | Phase I/II: AIDS 2001, 15:33-45 |
| S1360 | Shionogi Pharmaceuticals | Phase I/II PK currently enrolling Cornell, Columbia, UAB |
| TAK-449 | Takeda Pharmaceuticals | Company officials refused request for information |
| T-649 | Trimeris/Roche | Similar to T-1249; paper at 7/01 IAS meeting |
| Missing in Action | ||
| drug | pharmaceutical | comment |
| L-756,423/MK-944A | Merck | Reportedly moving into Phase II/III; paper at 7CROI |
| AG-1776/JE-2147 | Agouron (Pfizer) | All appearances suggest this drug is history. |
| L-708,906, L-731,988 | Merck | Hazuda, D.J., et al. Science 287(Jan. 28):646 (also, Science News) |
| Didox, Trimodox | Molecules for Health | Ribonucleotide reductase inhibitors – circa 1995 |
| AOP-RANTES | Gryphon Sciences | Animal (mouse) data only, J Virol 5/99, paper as summer IAS |
| FP-21399 | Lexigen Pharmaceuticals | Bruce Dezube again: J Infect Dis 2000 182:607-10 |
| PRO2000 | Genetics (formerly Procept) | Being tested as topical microbicide at Fenway Center |
| HGTV43 | Enzo Biochem, Inc. | Paper at summer IAS meeting |
| SJ-3366 | Samjin Pharmaceuticals Ltd. | Paper at 14th Intl. Conf. on Antiviral Research, 4/01 |
010910
TG010904
Copyright © 2001 - Treatment Action Group. TAGLine is published monthly by the Treatment Action Group (TAG), a 501(c)(3) non-profit treatment advocacy organization in New York City. email: , 611 Broadway, Ste. 612 · New York, NY 10012, phone: (212) 253-7922 · fax: (212) 253-7923.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .